In this article, we will take a look at the Top 5 Income Stocks with the Highest Upside Potential. For deeper discussion and analysis, read Top 10 Income Stocks with the Highest Upside Potential.
5. Becton, Dickinson and Company (NYSE:BDX)
Analayt Upside Potential: 21.24%
On June 12, BofA lowered its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $170 from $177. It reiterated a Neutral rating on the shares. The analyst noted that the firm’s services team continues to observe lower utilization across the healthcare sector. As a result, BofA is taking a more cautious approach to 2027 estimates for medtech companies, particularly since current valuations already reflect some utilization-related risks.
The analyst also expects inflation to remain a greater headwind in 2027, which could limit margin expansion across the medtech industry. Based on those assumptions, BofA reduced its 2027 estimates for several large-cap companies in its coverage universe that have exposure to both utilization trends and inflation pressures.
Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company. It develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Its products are used by healthcare institutions, physicians, life science researchers, clinical laboratories, and other healthcare professionals.
4. Medtronic plc (NYSE:MDT)
Analayt Upside Potential: 21.9%
On June 4, Truist reduced its price recommendation on Medtronic plc (NYSE:MDT) to $86 from $95. It reiterated a Hold rating on the shares. The firm pointed to a stronger-than-expected fourth quarter on the revenue side, with organic revenue growth coming in ahead of expectations. Margins, though, were softer than anticipated, while fiscal 2027 guidance largely matched forecasts. In its research note, Truist said it would need to see earnings per share growth move beyond the mid-single-digit to high-single-digit range before taking a more positive view on the stock.
Goldman Sachs analyst David Roman also trimmed his price target on Medtronic, lowering it to $83 from $84 while maintaining a Neutral rating. Roman said the company delivered fourth-quarter results that exceeded consensus expectations for organic revenue growth. Even with that stronger top-line performance, Goldman Sachs lowered its fiscal 2027 EPS estimate to $5.91 from $6.03. The adjustment was driven mainly by expectations for lower gross and operating margins, as well as the timing of Medtronic’s Diabetes spin-off.
Medtronic plc (NYSE:MDT) is an Ireland-based healthcare technology company that develops and provides medical technology solutions.
3. Gilead Sciences, Inc. (NASDAQ:GILD)
Analayt Upside Potential: 27.88%
On May 22, Reuters reported that Gilead Sciences, Inc. (NASDAQ:GILD) said its experimental drug for a rare and potentially fatal liver infection had received US approval. The U.S. Food and Drug Administration approved Hepcludex for the treatment of chronic hepatitis delta virus (HDV), a liver disease that affects people already infected with hepatitis B. The disease can lead to liver scarring, cancer, organ failure, and death.
According to the company, an estimated 40,000 to 80,000 people in the United States are living with HDV. Wendy Carter, acting director of the Office of Infectious Diseases in FDA’s Center for Drug Evaluation and Research, made the following statement:
“Today’s approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available.”
Data from a late-stage clinical trial supported the approval. About 48% of patients who received Hepcludex showed a meaningful improvement after 48 weeks, compared with 2% of patients whose treatment was delayed. The trial also showed that the virus became undetectable in patients the longer they remained on Hepcludex.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on advancing medicines to prevent and treat life-threatening diseases.
2. Comcast Corporation (NASDAQ:CMCSA)
Analayt Upside Potential: 35.2%
On June 12, Freedom Broker initiated coverage of Comcast Corporation (NASDAQ:CMCSA) with a Hold rating. It also set a $29 price target on the shares. The analyst noted that Comcast remains the largest broadband provider in the United States. In a research note, the firm said a broadband pricing reset is likely to put pressure on the company’s near-term average revenue per user and EBITDA. At the same time, Freedom Broker believes the move could help stabilize customer churn and rebuild lifetime value over the next 12 to 18 months. The firm added that Comcast’s “strong assets are offset by limited earnings visibility.”
On June 5, Rosenblatt lowered its price recommendation on Comcast to $24 from $30. It reiterated a Neutral rating on the shares. According to the analyst, a new concern for investors is broadband subscriber competition from Starlink, particularly with a potential SpaceX initial public offering on the horizon. The firm said that while this threat “seems unlikely to be really noticeable,” it still sees limited potential for a near-term re-rating of Comcast shares in the current environment.
Comcast Corporation (NASDAQ:CMCSA) is a global media and technology company. It provides broadband, wireless, and video services through Xfinity, Comcast Business, and Sky. The company also produces, distributes, and streams entertainment, sports, and news content through several brands.
1. Oracle Corporation (NYSE:ORCL)
Analayt Upside Potential: 45.05%
On June 11, Wedbush lowered its price recommendation on Oracle Corporation (NYSE:ORCL) to $240 from $275. It reiterated an Outperform rating on the shares. The firm noted that Oracle’s fourth-quarter results exceeded expectations on both revenue and earnings. It also highlighted the company’s solid fiscal 2027 guidance and said the closely watched remaining performance obligations (RPO) figure came in well above expectations.
According to Wedbush, demand for cloud services, AI training, and AI inferencing continues to accelerate, supporting Oracle’s growth outlook. The company also announced plans to raise about $40 billion through a combination of debt and equity financing in fiscal 2027, including a $20 billion at-the-market equity offering. Oracle said it does not expect to issue additional debt in 2026, as expanding AI infrastructure quickly and at scale remains a top priority.
Wedbush believes Oracle is making the right moves to capitalize on the growing AI opportunity. The firm added that the company’s record backlog provides the revenue visibility needed to support this aggressive infrastructure expansion.
Oracle Corporation (NYSE:ORCL) provides integrated application suites and secure, autonomous infrastructure through Oracle Cloud. The company operates across three business segments: cloud and license, hardware, and services.
While we acknowledge the potential of ORCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORCL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best S&P 500 Dividend Stocks to Buy Right Now and Billionaire Larry Robbins’ 10 Dividend Stock Picks
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
